Showing posts with label anxiety. Show all posts
Showing posts with label anxiety. Show all posts

Wednesday, 29 June 2011

Vilazodone: A Novel Antidepressant

Vilazodone was approved by the Food and Drug Administration in the U.S. earlier this year, but is just now becoming available in pharmacies for prescription use.  The drug is marketed in the U.S. under the trade name Viibyd.  It is novel in that it the only antidepressant that combines two mechanisms that can increase serotonin in the brain cortex: selective serotonin reuptake inhibition and partial agonism of the 5HT1A receptor.  There are multiple selective serotonin reuptake inhibitors, i.e. fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro).  

There are also compounds that have an agonistic effect on the 5HT1A receptor.  These include:
Antidepressants: trazodone, nefazodone
Antianxiety drugs: buspirone
Atypical antipsyhotics: aripiprazole, ziprasidone, clozapine, asenapine
Illicit drugs/compounds: MDMA (ecstasy), LSD, psylocybin, cannabidiol (cannabis)
Antimigraine compounds: ergotamine
Other compounds: yohimbine

The combination of SSRI and 5HT1A agonist effect may synergistically increase serotonergic transmission.  

Two published clinical trials on vilazodone are available on PubMed.  The table below summarizes some of the key findings from the two published trials.


The dose of vilazodone studied was 40 mg in both studies.  Because of the common occurrence of gastrointestinal side effects, doses are typically initiated at a smaller level and increased to 40 mg over the first week or so.  The pattern and prevalence of gastrointestinal side effects with vilazodone appears similar to levels seen in previous SSRI trials.  Although headache was commonly reported with vilazodone, the rate did not differ from the rate endorsed by placebo.  Dizziness, dry mouth, insomnia and abnormal dreaming were endorsed at a higher level with vilazodone but by less than 10% of the subjects.

Although vilazodone was statistically superior to placebo on almost all depression measures, it was not statistically superior in remission rates in the Kahn study.  This finding along with the relatively low absolute response rate of 27.3% in the vilazodone group is a little disappointing.

The response and remission rates found in these two studies were similar to SSRIs.  Head to head comparison with an SSRI would be informative to see if vilazdone has any effectiveness or adverse event superiority.  Sexual side effects are common with the SSRIs and the two randomized vilazodone studies reported no difference in sexual side effects between vilazodone and placebo.  Additionally, the Rickels study showed some evidence for anxiety symptom reduction.  Clinical trials examining the effectiveness of vilazodone for anxiety disorders will likely be soon completed.

Disclosure:  The author has no stock in the parent company of vilazodone (Forest Labs).  Additionally no honoraria or research grant support has been received related to this drug.  The author received no reimbursement for writing this post and the comments are entirely those of the author.

Information on the agonists for the 5HT1A receptor obtained from Wikipedia.

Chemical molecular structure of vilazodone from Creative Commons file at Wikepedia by author Meodipt.


Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, & Reed CR (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 70 (3), 326-33 PMID: 19284933


Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, & Reed CR (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. The Journal of clinical psychiatry, 72 (4), 441-7 PMID: 21527122

Tuesday, 31 May 2011

Brief Behavioral Therapy for Insomnia in Older Adults

Insomnia is a common complaint in the general population and among patients treated by primary care physicians.  This is particularly true for older adults who experience physiological changes in sleep with aging.  Clinicians commonly prescribe hypnotics for insomnia and the use of these types of drugs is increasing in the United States and elsewhere.  Behavioral and psychological interventions may be overlooked or bypassed in the sequencing of interventions for complaints of insomnia.

 I had previously posted on the promise of cognitive behavioral therapy for insomnia.  This therapy appears to be effective across a variety of patient groups including those with an underlying psychiatric diagnosis.  Now, a recent study in elderly subjects finds support for an even briefer intervention for those with primary insomnia.

Buysse and colleagues from the University of Pittsburgh and the Cleveland Clinic have recently published a randomized control trial of brief behavioral therapy intervention (BBTI) for primary insomnia in a group of adults averaging 71-72 years of age.  The brief intervention included direct contact with a single masters level nurse practitioner for an initial 45 to 60 minute session followed by a 20 minute direct contact session in 2 weeks.  Two 20-minute phone sessions were scheduled at one and three weeks following the initial contact session.  The authors note the sessions focused on customizing for each subject the four key elements of sleep education and stimulus control:

  1. reduce the total amount of time in bed
  2. get up at the same time daily regardless of sleep duration
  3. do not go to bed unless feeling sleepy
  4. do not stay in bed unless asleep

The control group was provided educational material that included information related to behavioral treatment of insomnia but did not include personalized contact session with the nurse practitioner.  Outcome was measured by whether subjects continued to meet criteria for insomnia as well as other secondary measures.

The BBTI group demonstrated a 67% response rate compared to only 25% response in the control group.  Remission of an insomnia diagnosis was noted in 55% of the BBTI group compared to only 13% of the control.  Most psychometric, sleep diary and actigraphy measures improved more in the BBTI group more than the control group.  Interestingly, there were no differences between the groups in polysomnography sleep lab measures including sleep latency, total sleep time and sleep efficiency.

The authors note attractive features of BBTI including:

  • it is easily taught to nurse practitioners and other clinicians
  • it includes a workbook that allows patients to follow exercises aimed at reducing insomnia
  • the strict behavioral approach limits some of the stigma associated with psychological treatment approaches in primary care

This study supports a stepped care approach for older adults with primary insomnia.  Following careful assessment to rule out another sleep disorder, i.e. sleep apnea or an untreated psychiatric disorder, i.e. depression or anxiety disorder, a trial of brief behavioral therapy may be a good first step.  Patients who fail to respond to this step may be candidates for consideration of hypnotic or other pharmacological interventions.

Photo of Lilly Pad Flower Bloom from Maui Courtesy of Yates Photography

Buysse, D., Germain, A., Moul, D., Franzen, P., Brar, L., Fletcher, M., Begley, A., Houck, P., Mazumdar, S., Reynolds, C., & Monk, T. (2011). Efficacy of Brief Behavioral Treatment for Chronic Insomnia in Older Adults Archives of Internal Medicine, 171 (10), 887-895 DOI: 10.1001/archinternmed.2010.535

This post was chosen as an Editor's Selection for ResearchBlogging.org